REGULATORY

• Shionogi COVID Jab Up for PAFSC Review Again after Efficacy Questions; Pfizer’s Zavicefta and Lots More on Roster
  May 13, 2024

• Apply Elective Care Scheme to Original Biologics with Biosimilars: Professor to LDP
  May 10, 2024

• Jaypirca, Prevymis Sail Through MHLW Panel Review; Avigan’s SFTS Use on Hold
  May 10, 2024

• Researchers Urge Japan to Help Develop Domestic CAR-T Therapies
  May 9, 2024

• Japan Needs Special Law on Medical Data to Allow Access Without Patient Consent: JPMA
  May 8, 2024

• New LDP Project Team Boots Up for Healthcare Transformation
  May 8, 2024

• H5N1 Pre-Pandemic Flu Vaccine Selected for Stockpiling in FY2024
  May 7, 2024

• Diagnostics of Original Biologics Can Be Used for Biosimilars Too: MHLW
  May 7, 2024

• MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
  April 30, 2024

• Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
  April 30, 2024

• Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
  April 30, 2024

• MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
  April 26, 2024

• Jaypirca, Prevymis, Relvar and More on MHLW Panel Agenda for May 9
  April 26, 2024

• Regulation Panel’s Final Report Specifies Exemptions for All-Case PMS
  April 25, 2024

• Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod
  April 25, 2024

• BMS’s Sotyktu to Face Price Cuts under CEA Scheme
  April 25, 2024

• Lawmakers’ League for Generics to Urge Rethink of Off-Year Price Revisions to Health Minister
  April 24, 2024

• 12 Quasi-Original Drugs to Be Excluded from New Coverage Scheme
  April 23, 2024

• Japan Wants to See Positive Trends on Drug Development after Reform: Official
  April 23, 2024

• Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
  April 23, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• 57
• …
• Next ›
• 最終 »